Business Wire

Fluence Launches RAPTR, a High-Output LED Replacement for Legacy Lighting Technology

Share

Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, today launched RAPTR, the company’s latest high-output lighting solution built to replace 1,000-watt, high-pressure sodium (HPS) fixtures and maximize energy efficiency.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220609005332/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Fluence today launched RAPTR, the company’s latest high-output lighting solution built to replace 1,000-watt, high-pressure sodium fixtures and maximize energy efficiency. (Photo: Business Wire)

Greenhouse and indoor growers are increasingly seeking more efficient, higher-output lighting solutions to reduce installation, operating and maintenance costs while increasing yield and plant quality. Recognizing the importance of maintaining consistency in harvest schedules while accommodating specific energy requirements, Fluence designed RAPTR to help enable cultivators to seamlessly retrofit their lighting solutions. In most cases, existing HPS electrical infrastructure such as cables or distribution panels can be reused for RAPTR—making it a true plug-and-play solution.

“Retrofitting a facility with LED technology opens the door to more light, creates opportunities for greater yields and ultimately increases revenue,” said Jordon Musser, chief product officer of Fluence. “RAPTR is designed to lower operating expenses for cultivators, increase light levels or even achieve both without changing the existing facility layout.”

Fluence’s ongoing global research exploring the effects of LED lighting on cannabis and produce crops has consistently shown that higher light intensities boost production at a nearly one-to-one ratio. Multiple Fluence research studies and customer trials found that, for every 1% increase in photosynthetic photon flux density (PPFD), growers are achieving a corresponding 1% increase in yield. For commercial produce growers, increasing light output is certainly desirable but cannot come at the expense of energy efficiency. RAPTR achieves higher light levels than its HPS equivalent—boosting yields for cannabis and produce growers—while helping to optimize a facility’s energy usage.

“We are in the business of meeting a grower’s goals, whether through a 100% LED lighting strategy or a hybrid approach,” said David Cohen, CEO of Fluence. “Adding RAPTR to our suite of lighting solutions gives growers yet another option to optimize their facilities based on what retailers and consumers want. We look forward to collaborating with our global cultivators to design best-in-class lighting strategies tailored to their environments using RAPTR.”

Purposely designed to mitigate surface dirt and dust collection, RAPTR fixtures are IP67-rated and feature powder-coated surfaces for easy cleaning and chemical resistance. RAPTR will be featured inside Fluence’s booth (No. 05.524) at GreenTech Amsterdam from June 14 to June 16.

For more information on RAPTR, Fluence and the company’s extended portfolio of luminaires and lighting controls, visit www.fluence.science.

About Fluence

Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Fluence,
Emma Chase
pr@fluencebioengineering.com
C: 512-917-4319

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye